AIA Group Ltd Buys 1,052 Shares of Regeneron Pharmaceuticals, Inc. $REGN

AIA Group Ltd raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 8,460 shares of the biopharmaceutical company’s stock after purchasing an additional 1,052 shares during the quarter. AIA Group Ltd’s holdings in Regeneron Pharmaceuticals were worth $6,537,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Brighton Jones LLC lifted its position in Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $226,000. Arrowstreet Capital Limited Partnership bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $3,183,000. Gabelli Funds LLC raised its stake in shares of Regeneron Pharmaceuticals by 3.0% in the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after buying an additional 55 shares in the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of Regeneron Pharmaceuticals by 18.8% during the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after acquiring an additional 5,120 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $676.69 on Monday. The firm has a market cap of $71.54 billion, a PE ratio of 16.49, a price-to-earnings-growth ratio of 1.50 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $821.11. The stock’s 50 day simple moving average is $640.99 and its 200 day simple moving average is $717.97. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $8.22 EPS. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Negative Sentiment: Multiple law firms announced or promoted securities class-action activity tied to REGN, including a newly filed class action and related investor deadline notices. These developments can weigh on sentiment because they highlight alleged disclosure issues and raise the risk of legal costs or settlement uncertainty. Article: Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
• Negative Sentiment: Additional reminders from Faruqi & Faruqi, Robbins LLP, Levi & Korsinsky, and Bragar Eagel & Squire kept the lawsuit story in focus, reinforcing legal overhang for shareholders. Article: REGN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc.
• Neutral Sentiment: A market commentary piece said Regeneron has rebounded and may still look undervalued, but also questioned whether the upside is already reflected in the shares, making the stock’s near-term direction less clear. Article: Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In?
• Neutral Sentiment: Brokerage coverage cited by American Banking News said REGN carries a “Moderate Buy” consensus, which supports the long-term outlook but is less likely to move the stock immediately than the litigation headlines. Article: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on REGN. Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research report on Monday, May 18th. Sanford C. Bernstein cut their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Barclays decreased their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Finally, JPMorgan Chase & Co. dropped their target price on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $787.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.